Canosa Stefano, Carosso Andrea Roberto, Mercaldo Noemi, Ruffa Alessandro, Evangelista Francesca, Bongioanni Francesca, Benedetto Chiara, Revelli Alberto, Gennarelli Gianluca
Obstetrics and Gynecology 1U, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, Sant'Anna Hospital, University of Turin, 10126 Turin, Italy.
Livet, GeneraLife IVF, 10126 Turin, Italy.
J Clin Med. 2022 Mar 13;11(6):1575. doi: 10.3390/jcm11061575.
We retrospectively studied a real-life population of 1470 women undergoing IVF, with poor/suboptimal/normal ovarian responsiveness to controlled ovarian stimulation (COS), comparing the cumulative live birth rate (cLBR) when COS was performed using rFSH alone or rFSH + rLH in a 2:1 ratio. Overall, we observed significantly higher cLBR in the rFSH alone group than in the rFSH + rLH group (29.3% vs. 22.2%, p < 0.01). However, considering only suboptimal/poor responders (n = 309), we observed comparable cLBR (15.6% vs. 15.2%, p = 0.95) despite the fact that patients receiving rFSH + rLH had significantly higher ages and worse ovarian reserve markers. The equivalent effectiveness of rFSH + rLH and rFSH alone was further confirmed after stratification according to the number of oocytes retrieved: despite basal characteristics were still in favor of rFSH alone group, the cLBR always resulted comparable. Even subdividing patients according to the POSEIDON classification, irrespective of differences in the baseline clinical characteristics in favor of FSH alone group, the cLBR resulted comparable in all subgroups. Despite the retrospective, real-life analysis, our data suggest that rLH supplementation in COS may represent a reasonable option for patients with predictable or unexpected poor/suboptimal ovarian responsiveness to FSH, those matching the Bologna criteria for poor responsiveness, and those included in the POSEIDON classification.
我们回顾性研究了1470名接受体外受精(IVF)的女性的实际人群,这些女性对控制性卵巢刺激(COS)的卵巢反应性较差/次优/正常,比较了单独使用重组促卵泡素(rFSH)或按2:1比例使用rFSH + 重组促黄体素(rLH)进行COS时的累积活产率(cLBR)。总体而言,我们观察到单独使用rFSH组的cLBR显著高于rFSH + rLH组(29.3%对22.2%,p < 0.01)。然而,仅考虑反应次优/较差的患者(n = 309),尽管接受rFSH + rLH的患者年龄显著更大且卵巢储备指标更差,但我们观察到cLBR相当(15.6%对15.2%,p = 0.95)。根据获卵数分层后,进一步证实了rFSH + rLH和单独使用rFSH具有同等效力:尽管基础特征仍有利于单独使用rFSH组,但cLBR始终相当。即使根据POSEIDON分类对患者进行细分,无论基线临床特征存在有利于单独使用FSH组的差异,所有亚组的cLBR均相当。尽管是回顾性的实际分析,但我们的数据表明,对于对FSH有可预测或意外的较差/次优卵巢反应性的患者、符合博洛尼亚反应不良标准的患者以及POSEIDON分类中的患者,在COS中补充rLH可能是一个合理的选择。